Source file signed link, expires in 15 minutes
Extracted text 7
Page 1
The original financial statements included herein
are in the Indonesian language.
PT INDOFARMA (PERSERO) TBK PT INDOFARMA (PERSERO) TBK
(d/h PT INDOFARMA TBK) (Formerly PT INDOFARMA TBK)
LAPORAN POSISI KEUANGAN STATEMENT OF FINANCIAL POSITION
Tanggal 30 Juni 2026 As of June 30, 2026
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/
30 Juni 2026/ 31 Desember 2025/
June 30, 2026 Notes December 31, 2025
ASET ASSETS
ASET LANCAR CURRENT ASSETS
2g, 5, 40,
Kas dan setara kas 4.403.493.302 41b, 43 5.686.138.621 Cash and cash equivalents
Piutang usaha - bersih Trade receivables - net
14.636.147.927 2h, 7, 40,
Pihak berelasi 41b, 43 14.252.393.709 Related parties
2h, 7,
Pihak ketiga 5.189.352.693 40, 43 4.444.727.434 Third parties
Piutang lain-lain - bersih Other receivables - net
2h, 8,
Pihak berelasi - 41b, 43 - Related parties
2h, 8,
Pihak ketiga - 43 - Third parties
Persediaan - bersih 53.796.314.371 2i, 9 65.551.930.887 Inventories - net
Pajak dibayar di muka 150.893.204 36a - Prepaid taxes
Uang muka dan biaya Advances and
dibayar di muka - bersih 21.918.915.596 2j, 10, 41b 29.296.773.041 prepayments - net
Aset pengembalian dana -
bersih - 4 - Right of return assets - net
Aset lancar lainnya - bersih - 6, 43 - Other current assets - net
JUMLAH ASET TOTAL CURRENT
LANCAR 100.095.117.093 119.231.963.692 ASSETS
ASET TIDAK LANCAR NON-CURRENT ASSETS
Investasi pada entitas
asosiasi 2.318.660.000 3, 11, 41b 2.318.660.000 Investment in associates
Aset keuangan tersedia 2f, 12 Financial assets available
untuk dijual - bersih - 41b, 43 - for sale - net
2w, 3,
Aset pajak tangguhan 75.863.340.918 36e 75.821.274.353 Deferred tax assets
2k, 3, Property, plant, and
Aset tetap - bersih 330.577.068.415 4, 13 336.587.353.078 equipment - net
Aset hak guna - bersih - 2y, 14 - Right-of-use assets - net
Aset takberwujud - bersih 1.740.201.386 2l, 15 1.788.992.078 Intangible assets - net
2m, 4,
Properti investasi - bersih 240.000.000 16 240.000.000 Investment property - net
Aset tidak lancar yang Abandoned non-current
akan ditinggalkan - bersih - 2o, 17 - assets - net
Aset tidak lancar lainnya - Other non-current
bersih - 18 - assets - net
JUMLAH ASET TOTAL NON-
TIDAK LANCAR 410.739.270.719 416.756.279.509 CURRENT ASSETS
JUMLAH ASET 510.834.387.812 535.988.243.201 TOTAL ASSETS
1
Catatan atas laporan keuangan The accompanying notes to the
terlampir merupakan bagian yang tidak terpisahkan dari financial statements form an integral part of these
laporan keuangan secara keseluruhan financial statements taken as a whole
Page 2
The original financial statements included herein
are in the Indonesian language.
PT INDOFARMA (PERSERO) TBK PT INDOFARMA (PERSERO) TBK
(d/h PT INDOFARMA TBK) (Formerly PT INDOFARMA TBK)
LAPORAN POSISI KEUANGAN (lanjutan) STATEMENT OF FINANCIAL POSITION (continued)
Tanggal 30 Juni 2026 As of June 30, 2026
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/
30 Juni 2026/ 31 Desember 2025/
June 30, 2026 Notes December 31, 2025
LIABILITAS DAN LIABILITIES AND
DEFISIENSI EKUITAS EQUITY DEFICIENCY
LIABILITAS LIABILITIES
LIABILITAS JANGKA CURRENT
PENDEK LIABILITIES
Utang usaha jangka pendek Short-term trade payables
19, 40,
Pihak berelasi 1.085.355.311 41b 1.085.355.311 Related parties
Pihak ketiga 46.226.730.143 19, 40 16.302.389.139 Third parties
Pinjaman kepada pemegang 2r, 26, Short-term shareholders
saham jangka pendek 250.723.449.031 44a, 44b 245.282.310.558 loan
2q, 20,
Pinjaman bank jangka 44a,
pendek 44b - Short-term bank loans
Biaya yang masih harus 2u, 21,
dibayar 38.169.217.053 43, 44a 36.330.921.453 Accrued expenses
Kewajiban pengembalian
dana 845.727.289 22 845.727.289 Refund liabilities
Liabilitas hak guna 2y, 23, 43 - Lease liabilities
Utang pajak 315.846.034.279 36 314.496.619.725 Tax payables
Kewajiban kontrak 3.903.082.406 24 18.103.318.541 Contract liability
Liabilitas imbalan kerja
jangka pendek 868.148.877 2v, 25a, 44 206.952.509 Short-term employee benefit
JUMLAH LIABILITAS TOTAL CURRENT
JANGKA PENDEK 657.667.744.389 632.653.594.525 LIABILITIES
LIABILITAS JANGKA NON-CURRENT
PANJANG LIABILITIES
Utang usaha jangka panjang Long-term trade liability
Pihak berelasi 11.477.571.675 2f, 19 11.477.571.675 Related parties
Pihak ketiga 109.673.271.461 2f, 19 143.797.137.081 Third parties
Pinjaman kepada pemegang 2r, 26, Long-term shareholders
saham jangka panjang 398.925.482.764 44a, 44b 384.453.324.071 loans
2q, 20,
Pinjaman bank jangka 44a,
panjang 73.163.011.668 44b 70.549.228.251 Long-term bank loans
Liabilitas imbalan kerja jangka Long term employee
panjang - 2v, 25b - benefit
JUMLAH LIABILITAS TOTAL NON-
JANGKA PANJANG 593.239.337.568 610.277.261.078 CURRENT LIABILITIES
JUMLAH LIABILITAS 1.250.907.081.957 1.242.930.855.603 TOTAL LIABILITIES
2
Catatan atas laporan keuangan The accompanying notes to the
terlampir merupakan bagian yang tidak terpisahkan dari financial statements form an integral part of these
laporan keuangan secara keseluruhan financial statements taken as a whole
Page 3
The original financial statements included herein
are in the Indonesian language.
PT INDOFARMA (PERSERO) TBK PT INDOFARMA (PERSERO) TBK
(d/h PT INDOFARMA TBK) (Formerly PT INDOFARMA TBK)
LAPORAN POSISI KEUANGAN (lanjutan) STATEMENT OF FINANCIAL POSITION (continued)
Tanggal 30 Juni 2026 As of June 30, 2026
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/
30 Juni 2026/ 31 Desember 2025/
June 30, 2026 Notes December 31, 2025
DEFISIENSI EKUITAS EQUITY DEFICIENCY
DEFISIENSI EKUITAS
YANG DAPAT EQUITY DEFICIENCY
DIATRIBUSIKAN ATTRIBUTABLE TO
KEPADA PEMILIK OWNERS OF THE
ENTITAS INDUK PARENT ENTITY
Modal saham –
Modal dasar
10.000.000.000
saham. Modal
ditempatkan dan Share capital –
disetor penuh . Authorized-
sebanyak 10,000,000,000 shares,
3.099.267.500 lembar Issued and fully paid
saham dengan 3,099,267,500 shares with
nominal Rp100 per par value of Rp100 per
lembar 309.926.750.000 2s, 27 309.926.750.000 share
Tambahan modal disetor 81.120.060.644 28 81.120.060.644 Additional paid-in capital
Komponen ekuitas lainnya 144.998.628.449 29 144.998.628.449 Other equity component
Cadangan aktuaria - - Actuarial reserve
Cadangan revaluasi aset 190.619.150.276 190.619.150.276 Revaluation reserve
Saldo laba/ (akumulasi Retained earnings/
defisit): (accumulated deficit):
Telah ditentukan
penggunaannya 1.271.553.449 1.271.553.449 Appropriated
Belum ditentukan
penggunaannya (1.468.008.836.963) (1.434.878.755.220) Unappropriated
Total defisiensi ekuitas
yang dapat Total equity deficiency
diatribusikan kepada attributable to owners of
pemilik entitas induk (740.072.694.145) (706.942.612.402) the parent entity
Kepentingan
nonpengendali - - Non-controlling interests
JUMLAH DEFISIENSI TOTAL EQUITY
EKUITAS (740.072.694.145) (706.942.612.402) DEFICIENCY
JUMLAH LIABILITAS
DAN DEFISIENSI TOTAL LIABILITIES AND
EKUITAS 510.834.387.812 535.988.243.201 EQUITY DEFICIENCY
3
Catatan atas laporan keuangan The accompanying notes to the
terlampir merupakan bagian yang tidak terpisahkan dari financial statements form an integral part of these
laporan keuangan secara keseluruhan financial statements taken as a whole
Page 4
The original financial statements included herein
are in the Indonesian language.
PT INDOFARMA (PERSERO) TBK PT INDOFARMA (PERSERO) TBK
(d/h PT INDOFARMA TBK) (Formerly PT INDOFARMA TBK)
LAPORAN LABA RUGI DAN PENGHASILAN STATEMENT OF PROFIT OR LOSS AND OTHER
KOMPREHENSIF LAIN COMPREHENSIVE INCOME
Untuk Periode Enam Bulan yang berakhir pada For the Six-month period ended
Tanggal 30 Juni 2026 June 30, 2026
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/
30 Juni 2026/ 30 Juni 2025/
June 30, 2026 Notes June 30, 2025
Penjualan bersih 79.043.913.365 2x, 30 67.028.581.838 Net sales
Beban pokok penjualan (71.125.772.453) 31 (76.989.198.111) Cost of goods sold
RUGI BRUTO 7.918.140.912 (9.960.616.273) GROSS LOSS
Beban penjualan (594.570.993) 32 (5.871.846.658) Selling expenses
Beban umum dan General and administrative
administrasi (12.684.566.761) 33 (24.940.313.200) expenses
Keuntungan lain-lain -
bersih (581,079,811) 35 (1.986.399.424) Other income - net
RUGI USAHA (5,942,076,652.92) (42.759.175.555) OPERATING LOSS
Beban keuangan (27.402.286.033) 34 (1.533.101.867) Financial expenses
Bagian laba bersih dari Equity in net profit of
entitas asosiasi 172,214,378 11 - associates
RUGI SEBELUM PAJAK (33.172.148.308) (44.292.277.422) LOSS BEFORE TAX
BEBAN PAJAK
PENGHASILAN INCOME TAX EXPENSE
Pajak kini 2w, 36d - Current tax
Pajak tangguhan 42.066.565 2w, 36c 740.189.501 Deferred tax
JUMLAH BEBAN
PAJAK TOTAL INCOME TAX
PENGHASILAN 42.066.565 740.189.501 EXPENSES
RUGI PERIODE LOSS FOR
BERJALAN (33.130.081.743) (43.552.087.921) THE PERIOD
PENGHASILAN/
(KERUGIAN) OTHER
KOMPREHENSIF COMPREHENSIVE
LAIN INCOME/(LOSS)
Pos-pos yang tidak akan Items that will not be
direklasifikasi ke reclassified to profit or
laba rugi loss
Pengukuran kembali
liabilitas imbalan Remeasurement of post
pascakerja - - employment benefit
Pajak penghasilan terkait - - Related income tax
Pengukuran nilai wajar Measurement of fair
melalui penghasilan value through other
komprehensif lain - - comprehensive income
JUMLAH PENGHASILAN
(KERUGIAN) TOTAL OTHER
KOMPREHENSIF COMPREHENSIVE
LAIN - - INCOME (LOSS)
RUGI KOMPREHENSIF TOTAL COMPREHENSIVE
PERIODE LOSS FOR THE
BERJALAN (33.130.081.743) (43.552.087.921) PERIOD
4
Catatan atas laporan keuangan The accompanying notes to the
terlampir merupakan bagian yang tidak terpisahkan dari financial statements form an integral part of these
laporan keuangan secara keseluruhan financial statements taken as a whole
Page 5
The original financial statements included herein
are in the Indonesian language.
PT INDOFARMA (PERSERO) TBK PT INDOFARMA (PERSERO) TBK
(d/h PT INDOFARMA TBK) (Formerly PT INDOFARMA TBK)
LAPORAN LABA RUGI DAN PENGHASILAN STATEMENT OF PROFIT OR LOSS AND OTHER
KOMPREHENSIF LAIN (lanjutan) COMPREHENSIVE INCOME (continued)
Tahun yang berakhir pada tanggal Six-month period ended
30 Juni 2026 June 30, 2026
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/
30 Juni 2026/ 30 Juni 2025/
June 30, 2026 Notes June 30, 2025
Rugi yang dapat
diatribusikan kepada: Loss attributable to:
Pemilik entitas induk (33.130.081.743) (43.552.087.921) Owner of the parent entity
Kepentingan nonpengendali - - Non-controlling interests
Jumlah (33.130.081.743) (43.552.087.921) Total
Rugi komprehensif yang
dapat diatribusikan Comprehensive loss
kepada: attributable to:
Pemilik entitas induk (33.130.081.743) (43.552.087.921) Owner of the parent entity
Kepentingan nonpengendali - - Non-controlling interests
Jumlah (33.130.081.743) (43.552.087.921) Total
RUGI BERSIH PER
SAHAM (10,69) (14,05) NET LOSS PER SHARE
5
Catatan atas laporan keuangan The accompanying notes to the
terlampir merupakan bagian yang tidak terpisahkan dari financial statements form an integral part of these
laporan keuangan secara keseluruhan financial statements taken as a whole
Page 6
The original financial statements included herein
are in the Indonesian language.
PT INDOFARMA (PERSERO) TBK PT INDOFARMA (PERSERO) TBK
(d/h PT INDOFARMA TBK) (Formerly PT INDOFARMA TBK)
LAPORAN PERUBAHAN EKUITAS STATEMENT OF CHANGES IN EQUITY
Untuk Periode Enam bulan yang berakhir pada tanggal For the Six-month period ended
30 Juni 2026 June 30, 2026
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Total Ekuitas
Tambahan Saldo Laba / Retained Earnings
Modal Komponen Cadangan Pemilik Induk/ Kepentingan
Modal Nilai Wajar Cadangan
Disetor/ ekutitas lainnya/ Revaluasi/ Total Equity Pengendali/ Non Total Ekuitas/
Disetor/ OCI/ Aktuaria/
Fully Paid Other equity Revaluation Penggunaannya/ Penggunaannya/ Attributable to – Controlling Total Equity
Additional Paid FVOCI Actuarial reserve Appropriated Unappropriated
Capital component reserve Owner of the Interest
in Capital
Parents
December 31,
309.926.750.000 81.120.060.644 - (5.021.974.347) 11.426.067.007 203.293.717.754 1.271.553.449 (1.746.036.031.393) (1.144.019.856.886) (21.951.887) (1.144.041.808.773)
31 Desember 2024 2024
- - - - - - (77.989.296.702) (77.989.296.702) - (77.989.296.702)-
Rugi tahun berjalan Loss for the year
Penyelesaian program
- - - 5.135.195.522 - - - (5.135.195.522) - - -
imbalan kerja
- - - (113.221.175) - (12.674.567.478) - 394.281.768.397 381.493.979.744 21.951.887 381.515.931.631
Dampak dekonsolidasi
Restrukturisasi utang - - - - 133.572.561.442 - - - 133.572.561.442 - 133.572.561.442
pemegang saham
Balance as of
Saldo per
December 31,
309.926.750.000 81.120.060.644 - - 144.998.628.449 190.619.150.276 1.271.553.449 (1.434.878.755.220) (706.942.612.402) - (706.942.612.402)
31 Desember 2025 2025
- - - - - - (33,130,081,743) (33,130,081,743) - (33,130,081,743)
Rugi tahun berjalan Loss for the year
Balance as of
Saldo per
309.926.750.000 81.120.060.644 - - 144.998.628.449 190.619.150.276 1.271.553.449 (1,468,008,836,963) (740,072,694,145) - (740,072,694,145) June 30, 2026
30 Juni 2026
-
Catatan atas laporan keuangan 6 The accompanying notes to the
terlampir merupakan bagian yang tidak terpisahkan dari financial statements form an integral part of these
laporan keuangan secara keseluruhan financial statements taken as a whole
Page 7
The original financial statements included herein
are in the Indonesian language.
PT INDOFARMA (PERSERO) TBK PT INDOFARMA (PERSERO) TBK
(d/h PT INDOFARMA TBK) (Formerly PT INDOFARMA TBK)
LAPORAN ARUS KAS STATEMENT OF CASH FLOWS
Untuk Periode Enam Bulan yang berakhir pada For the Six-month period ended
Tanggal 30 Juni 2026 June 30, 2026
(Disajikan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
30 Juni 2026/ 30 Juni 2025/
June 30, 2026 June 30, 2025
CASH FLOWS FROM
ARUS KAS DARI OPERATING
AKTIVITAS OPERASI ACTIVITIES
Penerimaan kas dari Cash receipts from
pelanggan 71.041.775.170 53.532.237.950 customers
Pembayaran kas kepada Cash paid to suppliers
pemasok dan karyawan (69.128.473.723) (70.716.809.758) and employees
Arus kas bersih
digunakan untuk Net cash flows used in
aktivitas operasi 1.913.301.447 (17.184.571.808) operating activities
ARUS KAS DARI CASH FLOWS FROM
AKTIVITAS INVESTASI INVESTING ACTIVITIES
Penerimaan penghasilan Interest received from
bunga 21.034.307 41.112.069 bank
Acquisition of property,
Perolehan aset tetap - - plant, and equipment
Arus kas bersih diperoleh Net cash flows provided
dari/ (digunakan untuk) by/ (used in) investing
aktivitas investasi 21.034.307 41.112.069 activities
ARUS KAS DARI
AKTIVITAS CASH FLOWS FROM
PENDANAAN FINANCING ACTIVITIES
Pembayaran utang Payments of shareholder
pemegang saham (3.216.981.073) (20.392.548.175) loan
Penerimaan utang Receipts from shareholder
pemegang saham - 33.632.298.789 loan
Arus kas bersih
diperoleh dari aktivitas Net cash flows provided
pendanaan (3.216.981.073) 13.239.750.614 by financing activities
KENAIKAN NET DECREASE IN
(PENURUNAN) BERSIH CASH AND CASH
KAS DAN SETARA KAS (1.282.645.319) (3.903.709.125) EQUIVALENTS
CASH AND CASH
EQUIVALENTS AT THE
KAS DAN SETARA KAS BEGINNING OF THE
AWAL PERIODE 5.686.138.621 9.255.849.932 PERIOD
Pengaruh perubahan kurs Effects of foreign
mata uang asing - - exchange rate changes
CASH AND CASH
KAS DAN SETARA KAS EQUIVALENTS AT THE
AKHIR PERIODE 4.403.493.302 5.352.140.807 END OF THE PERIOD
*) Konsolidasian *) Consolidated
7
Catatan atas laporan keuangan The accompanying notes to the
terlampir merupakan bagian yang tidak terpisahkan dari financial statements form an integral part of these
laporan keuangan secara keseluruhan financial statements taken as a whole
Names mentioned 1 people and organisations named in the text · linked when the evidence is strong
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.